Patients with CML (chronic myelogenous leukemia) who have received constant treatment with Imatinib (Gleevec) have acquired point mutations in the tyrosine kinase domain of the BCR-ABL fusion gene. Especially, the T315I mutation is known to be a mutation associated with imatinib resistance and is observed with high frequency. It is important to monitor patients treated with the Imatinibby BCR-ABLfusion gene mutation test to prevent failure of therapy due to mutational drug resistance.
PNAClamp™ Mutation Detection Kit BCR-ABL
For the detection of the BCR-ABL-associated T315I mutation
Cat. No. PNAC-7001
Other products
BUFFER PBS (PHOSPHATE BUFFERED SALINE) 100 ML TABLETS
50 tablets for 100 mL each one.
PANAMutyper™ Screening Kit EML4-ALK
For the detection of EML4-ALK mutations associated with lung cancer...
Biospin Total RNA Extraction Kit-100T-PCR/RT-PCR KIT(BSC63M1)
Effective kit to isolate total RNA from different sources. Simple,...
Bactotype Mycoplasma Mg/Ms PCR Kit (24 reactions) BIRDS
Cat. No: BT288103 Kit designed for the simultaneous detection of...